BM‐MSC vs no treatment
Respiratory function: change in FVC% (mean change from baseline to 12 months) · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
1 finding from 1 review
- Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 56 participantsLow